Searched over 200M research papers
10 papers analyzed
Most studies suggest metformin can lead to modest weight loss and improvements in BMI, especially in individuals with obesity or type 2 diabetes, while other studies indicate its effectiveness as a weight loss drug requires further research.
15 papers analyzed
20 papers analyzed
Metformin is primarily known as a first-line treatment for Type 2 diabetes, but its potential effects on weight loss have garnered significant interest. This article synthesizes findings from multiple studies to evaluate whether metformin can aid in weight loss across different populations.
A meta-analysis focusing on individuals over 60 years old found that metformin treatment led to a modest reduction in body weight. Specifically, participants experienced an average weight loss of 2.23 kg compared to placebo groups. Additionally, metformin improved lipid profiles, reducing total cholesterol and LDL levels, which may contribute to overall cardiovascular health.
A broader meta-analysis encompassing various populations revealed that metformin induces a modest reduction in BMI, particularly in individuals with simple obesity (BMI >35 kg/m²). The study highlighted that the most significant weight loss occurred within the first six months of treatment, with diminishing returns thereafter.
Research on metformin's efficacy in younger populations shows mixed results. A systematic review found that metformin led to a small but significant reduction in BMI and body weight in children and adolescents . However, the weight loss was generally modest and varied depending on adherence, dosage, and the presence of lifestyle interventions .
In adults, metformin has been shown to produce small but consistent weight reductions. A review of long-term studies indicated that metformin helps mitigate weight gain associated with other antidiabetic treatments and can lead to weight loss in obese nondiabetic populations. Another study found that metformin reduced body weight and waist circumference significantly over a 10-year period, with the degree of weight loss closely linked to adherence.
Metformin has also been studied in populations with specific conditions such as schizophrenia and schizoaffective disorder. A study found that metformin led to a modest weight loss of 3 kg over 16 weeks in overweight patients with these conditions, along with improvements in BMI, triglyceride levels, and hemoglobin A1c.
The mechanisms by which metformin induces weight loss are not entirely clear but may involve reduced food intake and improved satiety. A study on women with non-insulin-dependent diabetes mellitus (NIDDM) found that metformin decreased calorie intake and hunger ratings, leading to significant weight loss over 24 weeks.
Overall, metformin appears to offer modest weight loss benefits across various populations, including the elderly, children, and adults with obesity. While the weight loss is generally small, it is consistent and can be enhanced with adherence to the medication and lifestyle interventions. Further research is needed to fully understand the mechanisms and optimize the use of metformin for weight loss.
Most relevant research papers on this topic